Q&A: Positive results with RNAi therapeutic for liver disease in patients with AATD

Arrowhead Pharmaceuticals Inc. announced 24-week liver biopsy results in patients from an open-label phase 2 clinical study of ARO-AAT, a second-generation investigational RNA interference therapeutic intended for treatment of a liver disease associated with alpha-1 antitrypsin deficiency.Healio Gastroenterology spoke with Javier San Martin, MD, chief medical officer at Arrowhead, about the promising results found during this ongoing study.Healio: What was the purpose of the study?San Martin: The purpose of AROAAT2002 was to demonstrate the effect of ARO-AAT on reducing the production of theRead More

Share on facebook
Share on twitter
Share on linkedin